Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Peptic Ulcer

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 62 articles: HTML format

Single Articles

October 2026
1. REMES-TROCHE JM, Valdovinos-Garcia LR, Gyawali CP, Vargas-Basurto JL, et al
   The TOP-GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non-Asian Population.
   Aliment Pharmacol Ther. 2026 Oct 3. doi: 10.1111/apt.71032.
   PubMed     Abstract available
   
   
   
2. MASSIRONI S, Lenti MV, Lahner E, Sabatino AD, et al
   Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis-From Real-World Exposure to Indication-Driven Reassessment. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Oct 3. doi: 10.1111/apt.71034.
   PubMed    
   
   
   September 2026
3. MASSIRONI S, Lenti MV, Lahner E, Sabatino AD, et al
   Letter: Temporal Alignment of Proton Pump Inhibitor Exposure and Gastric Neuroendocrine Neoplasm Risk in Autoimmune Gastritis. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Sep 28. doi: 10.1111/apt.71018.
   PubMed    
   
   
   
4. CALABRESE F, Savarino V, Savarino EV, Giannini EG, et al
   Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis-From Real-World Exposure to Indication-Driven Reassessment.
   Aliment Pharmacol Ther. 2026 Sep 25. doi: 10.1111/apt.71016.
   PubMed    
   
   
   
5. AZZI G, Al-Ukaidey S
   Letter: Temporal Alignment of Proton Pump Inhibitor Exposure and Gastric Neuroendocrine Neoplasm Risk in Autoimmune Gastritis.
   Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71003.
   PubMed    
   
   
   
6. MASSIRONI S, Lenti MV, Lahner E, Di Sabatino A, et al
   Editorial: Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis-Authors' Reply.
   Aliment Pharmacol Ther. 2026 Sep 18. doi: 10.1111/apt.70995.
   PubMed    
   
   
   
7. WALDUM H
   Editorial: Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis.
   Aliment Pharmacol Ther. 2026 Sep 11. doi: 10.1111/apt.70975.
   PubMed    
   
   
   
8. ZAVOS C
   Letter: Proton Pump Inhibitors in Autoimmune Gastritis.
   Aliment Pharmacol Ther. 2026 Sep 10. doi: 10.1111/apt.70974.
   PubMed    
   
   
   
9. MASSIRONI S, Lenti MV, Lahner E, Galbiati M, et al
   Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup.
   Aliment Pharmacol Ther. 2026 Sep 6. doi: 10.1111/apt.70954.
   PubMed     Abstract available
   
   
   August 2026
10. STURM L, Maasoumy B, Thimme R, Bettinger D, et al
    Letter: The Microbiome-Mediated Impact of Proton Pump Inhibitors on Spontaneous Bacterial Peritonitis-Authors' Reply.
    Aliment Pharmacol Ther. 2026 Aug 23. doi: 10.1111/apt.70939.
    PubMed    
    
    
    
11. WATANABE J, Sekiguchi H, Kanno T, Misawa K, et al
    Meta-Analysis: Prevalence of Non-Helicobacter pylori, Non-NSAID Peptic Ulcer Disease.
    Aliment Pharmacol Ther. 2026 Aug 10. doi: 10.1111/apt.70906.
    PubMed     Abstract available
    
    
    July 2026
12. SIMEONI S, Ponziani FR, Gasbarrini G, Gasbarrini A, et al
    Letter: The Microbiome-Mediated Impact of Proton Pump Inhibitors on Spontaneous Bacterial Peritonitis.
    Aliment Pharmacol Ther. 2026 Jul 30. doi: 10.1111/apt.70883.
    PubMed    
    
    
    June 2026
13. QUACH DT, Liou JM, Gisbert JP, Leung WK, et al
    Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.
    Aliment Pharmacol Ther. 2026 Jun 17. doi: 10.1111/apt.70798.
    PubMed     Abstract available
    
    
    
14. KITCHEN P, Maasoumy B, Bettinger D, Thimme R, et al
    Letter on 'Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors'. Authors' Reply.
    Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70781.
    PubMed    
    
    
    May 2026
15. YANG X, Zhao G
    Letter: Interpreting Apparent P-CAB Superiority for Antithrombotic-Associated Upper Gastrointestinal Bleeding.
    Aliment Pharmacol Ther. 2026 May 31. doi: 10.1111/apt.70771.
    PubMed    
    
    
    
16. MALIK MMUD
    Letter on 'Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors'.
    Aliment Pharmacol Ther. 2026 May 22. doi: 10.1111/apt.70747.
    PubMed    
    
    
    
17. SIBONI S, Sozzi M, Gyawali CP
    Editorial: The Milan Score as Supportive Evidence of Gastro-Oesophageal Reflux Disease. Authors' Reply.
    Aliment Pharmacol Ther. 2026 May 13. doi: 10.1111/apt.70729.
    PubMed    
    
    
    
18. YOON MJ, Lee S, Jung HK, Kim MH, et al
    P-CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study.
    Aliment Pharmacol Ther. 2026 May 9. doi: 10.1111/apt.70719.
    PubMed     Abstract available
    
    
    April 2026
19. CHAHUAN J, Savarino EV
    Editorial: The Milan Score as Supportive Evidence of Gastro-Oesophageal Reflux Disease.
    Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70697.
    PubMed    
    
    
    March 2026
20. QUICKERT S, Reuken PA
    Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis.
    Aliment Pharmacol Ther. 2026 Mar 8. doi: 10.1111/apt.70620.
    PubMed    
    
    
    February 2026
21. KITCHEN P, Schutte SL, Tergast TL, Maasoumy B, et al
    Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors.
    Aliment Pharmacol Ther. 2026 Feb 17. doi: 10.1111/apt.70593.
    PubMed     Abstract available
    
    
    January 2026
22. GISBERT JP, Parra P, Nyssen OP
    Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.
    Aliment Pharmacol Ther. 2026 Jan 19. doi: 10.1111/apt.70535.
    PubMed     Abstract available
    
    
    May 2025
23. SPINELLI I, Ianiro G
    Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition? Authors' Reply.
    Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70204.
    PubMed    
    
    
    
24. CRISTOFORI F, Dargenio VN, Francavilla R
    Letter: Helicobacter pylori and Eosinophilic Oesophagitis-Lost in Definition?
    Aliment Pharmacol Ther. 2025 May 20. doi: 10.1111/apt.70179.
    PubMed    
    
    
    
25. KAHRILAS PJ, Keefer L, Yadlapati R, Anastasiou F, et al
    Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.
    Aliment Pharmacol Ther. 2025;61:1437-1446.
    PubMed     Abstract available
    
    
    April 2025
26. SPINELLI I, Ianiro G
    Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70135.
    PubMed    
    
    
    
27. RAHMAN H
    Letter: Meta-Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Apr 10. doi: 10.1111/apt.70122.
    PubMed    
    
    
    
28. SHARMA P, Vaezi M, Unge P, Andersson K, et al
    Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis.
    Aliment Pharmacol Ther. 2025 Apr 4. doi: 10.1111/apt.70109.
    PubMed     Abstract available
    
    
    March 2025
29. SPINELLI I, Ianiro G
    Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply.
    Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70099.
    PubMed    
    
    
    
30. EMANUELE E, Minoretti P
    Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Mar 26. doi: 10.1111/apt.70075.
    PubMed    
    
    
    February 2025
31. SPINELLI I, Porcari S, Esposito C, Fusco W, et al
    Meta-Analysis: Inverse Association Between Helicobacter pylori Infection and Eosinophilic Oesophagitis.
    Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70042.
    PubMed     Abstract available
    
    
    
32. MIYAHARA S, Yamashina T, Ohyama T, Banno M, et al
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70011.
    PubMed    
    
    
    
33. CHUAH KH, Mahadeva S
    Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply.
    Aliment Pharmacol Ther. 2025 Feb 14. doi: 10.1111/apt.70025.
    PubMed    
    
    
    January 2025
34. FISCHMAN M, Elias A, Klein A, Cohen Y, et al
    Chronic Use of Proton Pump Inhibitors Is Associated With Reduced 30-Day Mortality From Acute Pancreatitis.
    Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18523.
    PubMed     Abstract available
    
    
    
35. TAYLOR S, Chen L, Dutt K, Boyapati R, et al
    Blood Group B May Reduce Risk of Rebleeding in Patients With Upper Gastrointestinal Haemorrhage due to Peptic Ulcer Disease.
    Aliment Pharmacol Ther. 2025 Jan 9. doi: 10.1111/apt.18485.
    PubMed     Abstract available
    
    
    December 2024
36. ARMSTRONG D, Hungin AP, Kahrilas PJ, Sifrim D, et al
    Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.
    Aliment Pharmacol Ther. 2024 Dec 30. doi: 10.1111/apt.18420.
    PubMed     Abstract available
    
    
    
37. HOWDEN CW, Katz P, DeVault KR, Metz DC, et al
    Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro-Oesophageal Reflux Disease or Erosive Oesophagitis.
    Aliment Pharmacol Ther. 2024 Dec 25. doi: 10.1111/apt.18458.
    PubMed     Abstract available
    
    
    
38. SCHULZ C, Suerbaum S, Malfertheiner P
    Editorial: Helicobacter pylori Antimicrobial Susceptibility Testing-An Expanding Toolbox. Authors' Reply.
    Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18429.
    PubMed    
    
    
    
39. CHUAH KH, Loo QY, Hian WX, Khoo XH, et al
    Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor.
    Aliment Pharmacol Ther. 2024 Dec 2. doi: 10.1111/apt.18418.
    PubMed     Abstract available
    
    
    September 2024
40. IDALSOAGA F, Diaz LA, Ayares G, Cabrera D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease-Authors' reply.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18246.
    PubMed    
    
    
    
41. KOUNTOURAS J, Vardaka E, Zavos C, Chatzopoulos D, et al
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease.
    Aliment Pharmacol Ther. 2024 Sep 2. doi: 10.1111/apt.18220.
    PubMed    
    
    
    July 2024
42. KOUNTOURAS J, Polyzos SA, Kazakos E, Zavos C, et al
    Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18124.
    PubMed    
    
    
    
43. BANSAL SK, Bansal MB
    'Letter: Role of Helicobacter pylori and metabolic syndrome-related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18182.
    PubMed    
    
    
    
44. BAGER P, Dahlerup JF
    Letter: Post-endoscopic management after upper gastrointestinal bleeding-Replenishment of iron loss.
    Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18050.
    PubMed    
    
    
    
45. WANG Y, Pan Y
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18145.
    PubMed    
    
    
    
46. LYU C, Yang D, Xu H, He K, et al
    Letter: Reflections on the role of over-the-scope clips in high-risk upper gastrointestinal bleeding-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 15. doi: 10.1111/apt.18173.
    PubMed    
    
    
    
47. YOON JS, Lee JH
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients-Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 12. doi: 10.1111/apt.18167.
    PubMed    
    
    
    
48. SCHEINER B, Dominik N, Mandorfer M
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18144.
    PubMed    
    
    
    
49. KOUNTOURAS J, Polyzos SA, Kazakos E, Papanikolaou IS, et al
    Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease.
    Aliment Pharmacol Ther. 2024 Jul 3. doi: 10.1111/apt.18066.
    PubMed    
    
    
    April 2024
50. WANG J, Wen F, Zhao J
    Letter: Risks of proton pump inhibitor treatment in cirrhotic patients.
    Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17954.
    PubMed    
    
    
    March 2024
51. SHUNG DL, Laine L
    Review article: Upper gastrointestinal bleeding - review of current evidence and implications for management.
    Aliment Pharmacol Ther. 2024 Mar 22. doi: 10.1111/apt.17949.
    PubMed     Abstract available
    
    
    
52. KRAUSE AJ, Yadlapati R
    Review article: Diagnosis and management of laryngopharyngeal reflux.
    Aliment Pharmacol Ther. 2024;59:616-631.
    PubMed     Abstract available
    
    
    February 2024
53. YOON JS, Hong JH, Park SY, Kim SU, et al
    High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
    Aliment Pharmacol Ther. 2024 Feb 22. doi: 10.1111/apt.17909.
    PubMed     Abstract available
    
    
    
54. LON N, Engel S, Damholt A, Mortensen B, et al
    Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
    Aliment Pharmacol Ther. 2024;59:341-349.
    PubMed     Abstract available
    
    
    August 2023
55. GONG EJ, Jung HK, Lee B, Hong J, et al
    Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
    Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676.
    PubMed     Abstract available
    
    
    July 2023
56. WAUTERS L, Harris PR, Walker MM, Serrano CA, et al
    Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023;58:134-136.
    PubMed    
    
    
    May 2023
57. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort analysis. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1199-1200.
    PubMed    
    
    
    
58. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
    Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
    Aliment Pharmacol Ther. 2023;57:1186-1187.
    PubMed    
    
    
    
59. ARAI J, Hayakawa Y, Niikura R, Ihara S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis.
    Aliment Pharmacol Ther. 2023;57:1196-1198.
    PubMed    
    
    
    April 2023
60. HOWDEN CW, Shah S, Pendse SN, Offman E, et al
    Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526.
    PubMed     Abstract available
    
    
    
61. SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al
    A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510.
    PubMed     Abstract available
    
    
    March 2023
62. TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al
    Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease.
    Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum